Compare ARMP & HSDT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ARMP | HSDT |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | 21 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 383.7M | 77.6M |
| IPO Year | 1996 | N/A |
| Metric | ARMP | HSDT |
|---|---|---|
| Price | $8.05 | $2.08 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $15.00 | N/A |
| AVG Volume (30 Days) | 41.3K | ★ 337.9K |
| Earning Date | 03-16-2026 | 04-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 53.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $75.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.90 | $0.26 |
| 52 Week High | $13.75 | $25.50 |
| Indicator | ARMP | HSDT |
|---|---|---|
| Relative Strength Index (RSI) | 38.88 | 45.44 |
| Support Level | $5.14 | $1.78 |
| Resistance Level | $8.40 | $2.37 |
| Average True Range (ATR) | 0.94 | 0.19 |
| MACD | -0.46 | 0.03 |
| Stochastic Oscillator | 6.30 | 43.14 |
Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.
Solana Co is a publicly listed digital asset treasury established in partnership with Pantera and Summer Capital. The company is dedicated to acquiring Solana (SOL) and aims to maximize SOL per share by strategically leveraging capital market opportunities and on-chain activities. Through this model, Solana Company provides public market investors with efficient and direct exposure to Solana's long-term growth potential.